Therapeutics Acquisition Corp., Sponsored by RA Capital Management, L.P., Announces Closing of $135.7 Million Initial Public ...
10 Julho 2020 - 5:15PM
Business Wire
Therapeutics Acquisition Corp. (Nasdaq: TXAC) (the “Company”)
announced today that on July 10, 2020 it closed its initial public
offering of 13,570,000 shares of Class A common stock, including
1,770,000 shares issued pursuant to the exercise by the
underwriters of their over-allotment option. The offering was
priced at $10.00 per share, resulting in gross proceeds of
$135,700,000.
The Company, sponsored by RA Capital Management, L.P., is led by
Chairman and CEO Peter Kolchinsky PhD and CFO Matthew Hammond PhD.
The Company is a blank check company formed for the purpose of
effecting a business combination with one or more businesses in the
healthcare industry. The proceeds of the offering will be used to
fund such business combination.
The Company’s shares of Class A common stock began trading on
The Nasdaq Capital Market under the ticker symbol “TXAC” on July 8,
2020.
Jefferies LLC served as sole book runner for the offering.
The offering is being made only by means of a prospectus. Copies
of the prospectus may be obtained from: Jefferies LLC, Attn: Equity
Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New
York, NY 10002, by telephone: 877-821-7388 or by email:
Prospectus_Department@Jefferies.com.
Registration statements relating to these securities became
effective on July 7, 2020. This press release shall not constitute
an offer to sell or the solicitation of an offer to buy, nor shall
there be any sale of these securities in any state or jurisdiction
in which such an offer, solicitation or sale would be unlawful
prior to registration or qualification under the securities laws of
any such state or jurisdiction.
FORWARD-LOOKING STATEMENTS
This press release contains statements that constitute
“forward-looking statements,” including with respect to the initial
public offering and the anticipated use of the net proceeds. No
assurance can be given that the net proceeds of the offering will
be used as indicated. Forward-looking statements are subject to
numerous conditions, many of which are beyond the control of the
Company, including those set forth in the Risk Factors section of
the Company’s registration statement and preliminary prospectus for
the offering filed with the Securities and Exchange Commission
(“SEC”). Copies are available on the SEC’s website, www.sec.gov.
The Company undertakes no obligation to update these statements for
revisions or changes after the date of this release, except as
required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200710005428/en/
RA Capital Management, L.P. Matthew Hammond 617-778-2540
Therapeutics Acquisition (NASDAQ:TXAC)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Therapeutics Acquisition (NASDAQ:TXAC)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024